Mandate

Vinge advises industrifonden in connection with pharmalink’s capital raising of sek 96 million

October 08, 2013

Industrifonden and the Norwegian investment company, Investinor have invested a combined total of SEK 79 million in Pharmalink, the pharmaceuticals development company. Private investors have also contributed to the total capital raising of SEK 96 million. The funds will be used to further develop Pharmalink’s product portfolio.

Pharmalink is a pharmaceuticals company which improves and further develops existing pharmaceuticals. The company is currently conducting the Nefecon project for the treatment of inflammation of the kidneys and the Busulipo project for treatment prior to bone marrow transplantation.

Industrifonden has been a stakeholder in Pharmalink since 2004. The Norwegian investment company, Investinor is a new stakeholder.

Vinge partner Johan Larsson advised Industrifonden

Related

Vinge advises FAM AB on the acquisition of Aktiebolaget Näckström

Vinge has advised FAM AB on its acquisition of Aktiebolaget Näckström from Vectura Fastigheter AB. The principal assets of Aktiebolaget Näckström comprise the property Stockholm Näckström 6 (Arsenalsgatan 8) and Villa Täcka udden.
October 16, 2025

Vinge has advised FAM in connection with its investment in GreenIron

Vinge has advised FAM AB, owned by the Wallenberg Foundations, in connection with its investment in GreenIron H2 AB. Through the round, GreenIron raised in total SEK 125 million in additional funding from existing shareholders, with FAM now becoming the company’s largest owner.
October 16, 2025

Vinge has advised on the sale of Westcomp AB to Tången Industrikapital AB

Pursuant to the transaction, Tången acquires approximately 91 per cent of the shares in Westcomp.
October 15, 2025